WebFeb 6, 2024 · Pulmatrix Announces Year-End and Q4 Financial 2024 Results and Provides Corporate Update. Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical … WebClin Pulm Med. 2016 Sep;23(5):218-226. doi: 10.1097/CPM.0000000000000171. Authors Leah J Witt 1 , James J Curran 2 , Mary E Strek 1 Affiliations 1 Section of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Chicago Medicine, Chicago, IL 60637. 2 Section of Rheumatology, Department of Medicine, The University ...
PULMATRiX
WebApr 6, 2024 · PULM. Pulmatrix reports Q4 revenue $6.1M vs. $5.2M last year. Pulmatrix’s total cash and cash equivalents balance as of December 31, 2024 was $35.6M. The company anticipates that... 10d ago. PULM. Pulmatrix (PULM) Q4 Earnings Cheat Sheet. Pulmatrix (PULM) is scheduled to report 4th quarter earnings on 03/29/2024. WebJun 15, 2024 · The clinical trial will test the use of PULM-001 in patients in the early stages of COVID-19. The is one of very few phase III clinical trials for COVID therapies to obtain approval from both the U.S. Food and Drug Administration (FDA) and Health Canada. polymer clay takealot
Pulmonary and Critical Care Medicine Fellowship Program
WebNews & Media. Contact Us. 310-825-2631. Breadcrumb. Home; Departments; Medicine; Pulmonary, Critical Care & Sleep Medicine; Training Programs; Pulmonary, Critical Care & Sleep Medicine Pulmonary and Critical Care Medicine Fellowship Program Sub-navigation. Training Programs. WebJan 4, 2024 · Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology. Pulmatrix, Inc. (NASDAQ: PULM), a clinical … WebOct 21, 2024 · LEXINGTON, Mass., Oct. 21, 2024 -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced marketing and distribution partner Sensory Cloud's commercial launch … shank bosses